Expression of cell regulatory proteins in ovarian borderline tumors

Haaften-Day, Caroline van; Russell, Peter; Boyer, Cinda M.; Kerns, Billie‐Jo M.; Wiener, Jon R.; Jensen, Debra N.; Bast, Robert C.; Hacker, Neville F.

doi:10.1002/(sici)1097-0142(19960515)77:10<2092::aid-cncr19>3.0.co;2-q

Cited by 26 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p16 and p53, as regulator genes of cell proliferation and apoptosis, are main targets in the chromosomal changes. p53 gene inactivation is the most common defect in ovarian cancer with a 60% mutation rate in advanced stage ovarian carcinoma whereas immunohistochemical p53 expression in SBTs varies from 0 to 33,3% (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Ratio of p53 expression in SBTs is reported to be between benign and malignant tumors (15,(22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Expression of p16, p53, CD24, EpCAM and Calretinin in Serous Borderline Tumors of the Ovary

Aktaş

Bugdayci²,

Usubütün³

2012

TJPATH

View full text Add to dashboard Cite

ÖZAmaç: Over kanserinin yaygın olarak kabul gören patogenez modeline gore bir seröz borderline tümör invaziv olmadan önce, noninvaziv mikropapiller aşamaya geçer veya tipik bir seröz borderline tümör zemininde mikroinvazyon yaparak invaziv aşamaya geçer. Bu çalışmanın amacı seröz borderline tümörler ve over dışı lezyonlarının seröz over kanseri patogenezindeki rolünü immunohistokimyasal bir panelle incelemektir. Gereç ve Yöntem:Tipik, fokal mikropapiller, mikropapiller, mikroinvaziv, kistadenom ve düşük dereceli karsinom alanları içeren 46 olguluk seröz borderline tümör grubuna p16, p53, CD24, EpCAM ve kalretininden oluşan immünohistokimyasal bir panel uygulandı. Bu panelin degerlendirilmesi icin seröz borderline tümörler gibi kistik/ince duvarlı ve heterojen neoplazileri incelerken lineer bir kesite bakma imkanı vermesi nedeni ile daha avantajlı olan "cutting edge" matriks-benzeri doku arrayleri hazırlandı. Bulgular:Tümör supresör gen grubunda değerlendirilen iki işaretleyici ile diffüz, kuvvetli p53 ekspresyonu hiçbir olguda saptanmaz iken,olguların tümünde p16 ile kuvvetli, heterojen ekspresyon izlendi. Kalretinin ile mikropapiller tümörlerde fokal kuvvetli ekspresyon izlenirken, EpCAM ile aynı alanlarda ekspresyon kaybı saptandı. Hücre adezyon moleküllerinin ekspresyon lokalizasyonlarındaki değişikliklerin fenotipte değişme ve tümör progresyonu ile ilişkili olabileceğini destekler şekilde, peritoneal implantların saptandığı olgularda sitoplazmik ve kuvvetli CD24 ekspresyonu görüldü. Lenf nodu tutulumu ve mikroinvazyon alanlarında çembersel membranöz ve sitoplazmik CD24 ve EpCAM ekspresyonu görüldü.Sonuç: Bulgular, seröz over tümörü progresyonunun farklı aşamala-rına EpCAM, CD24, ve kalretinin immünohistokimyasal ekspresyon paternindeki değişikliklerin eşlik edebildiğini göstermektedir.Anahtar Sözcükler: Over tümörleri, p16 proteini, p53 antijeni, CD24 antijeni, EpCAM proteini, Calretinin ABSTRACTObjective: According to the widely accepted pathway, a serous borderline tumor becomes invasive either by progressing into a noninvasive micropapillary tumor or directly through microinvasion. Our objective was to investigate the role of serous borderline tumors and their accompanying extraovarian lesions in pathogenesis of serous ovarian cancer using immunohistochemistry as a tool. Material and Method:An immunohistochemical panel of p16, p53, CD24, EpCAM and calretinin was applied to cutting edge matrix assembly-like tissue arrays of 46 cases consisting of typical, focal micropapillary, micropapillary, microinvasive, cystadenoma, and low-grade carcinoma cases. These tissue arrays are better choices than conventional tissue arrays to examine thin walled and heterogenous neoplasia like serous borderline tumors as they facilitate the analysis with linear sections rather than a core.Results: For two tumor supressor gene markers; no diffuse and strong expression of p53, and strong and patchy/heterogenous expression of p16 were detected in all cases. Focal and strong calretinin expression was detected in micropapillary tu...

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of p16, p53, CD24, EpCAM and Calretinin in Serous Borderline Tumors of the Ovary

Aktaş

Bugdayci²,

Usubütün³

2012

TJPATH

View full text Add to dashboard Cite

show abstract

“…Most of the markers included in this category have been identified through approaches in which human cancer cells are used as an antigenic stimulus in animals to raise antibodies, which can then efficiently detect the antigen in human serum. A review of Table 1 suggests that CA 125 remains the best-documented and bestperforming single marker among the epithelial sialomucins currently described [2,6,47,48,54,63,91,94,98,101,102,108,112,116]. Sensitivity estimates vary from as low as 27% in some studies for early-staged disease to better than 90% for late-staged disease.…”

Section: Epithelial Sialomucinsmentioning

confidence: 99%

Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review

et al. 2004

View full text Add to dashboard Cite

“…The most extensively studied oncogenes in ovarian tumors are HER‐2/neu oncogene and K‐ras oncogene. Overexpression of the HER‐2/neu oncogene occurs in approximately 30% of EOC and correlates with poor survival, whereas in BTO 21% overexpression is found without a clinical correlation (41–43) . There is no clear correlation between FIGO stage and HER‐2/neu gene expression.…”

Section: Etiologymentioning

confidence: 99%

The management of borderline epithelial tumors of the ovary

Burger¹,

Prinssen²,

Baak³

et al. 2000

Int J Gynecol Cancer

View full text Add to dashboard Cite

The histopathological diagnosis and treatment of borderline epithelial tumors of the ovary (BTO) still pose problems to both pathologists and gynecologists. BTO is a disease of younger, fertile females and generally has an excellent prognosis. A minority of patients, however, succumb to this disease. A review of the literature is given addressing aspects of epidemiology, histology, treatment and prognosis, resulting in a proposal for the management of serous and mucinous borderline tumors of the ovary.

show abstract

Expression of cell regulatory proteins in ovarian borderline tumors

Cited by 26 publications

References 32 publications

Expression of p16, p53, CD24, EpCAM and Calretinin in Serous Borderline Tumors of the Ovary

Expression of p16, p53, CD24, EpCAM and Calretinin in Serous Borderline Tumors of the Ovary

Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review

The management of borderline epithelial tumors of the ovary

Contact Info

Product

Resources

About